NASDAQ:APTX

Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

Retrieved on: 
Jeudi, mars 30, 2023
Mental Health, Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Workforce, Inc., Addiction, Initiative, Opioid use disorder, Deficit spending, OUD, Research, APTX, Bangladesh Technical Education Board, Trial of the century, Yale School of Medicine, Dementia, Patient, Post-traumatic stress disorder, Administration, NIDA, Yale University, National Institute on Drug Abuse, Lewy body, Research and development, R, HEAL, NIH, PTSD, Video game, Pharmaceutical industry, Cryptocurrency

Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022.
  • In the analysis, NYX-783 did not demonstrate sufficient improvement on the study’s primary endpoint to support continued advancement of the development program by Aptinyx.
  • In March, Aptinyx engaged Ladenburg Thalmann as its exclusive financial advisor to assist in the company’s exploration and evaluation of strategic alternatives.
  • Net Loss: Net loss was $12.1 million for the fourth quarter of 2022 compared to a net loss of $19.6 million for the same period in 2021.

Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

Retrieved on: 
Lundi, février 27, 2023
Research, Mental Health, Neurology, Clinical Trials, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Deficit spending, Three-body problem, Post-traumatic stress disorder, Brain, Patient, NMDA, Dementia, Inc., Lewy body, Systemic disease, APTX, Pharmaceutical industry, PTSD

Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over placebo on the study’s efficacy endpoints.

Key Points: 
  • Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over placebo on the study’s efficacy endpoints.
  • The results do not support further development of NYX-458 by the company.
  • “We appreciate the dedication and contributions of patients, investigators, and the extensive team that worked on the study.
  • Across the overall study population, NYX-458 did not demonstrate clinically meaningful improvements over placebo on the study’s efficacy endpoints.

Aptinyx to Present at the SVB Securities Global Biopharma Conference

Retrieved on: 
Mardi, janvier 31, 2023
Biotechnology, Pharmaceutical, Health, Inc., APTX, Brain, Conference, Systemic disease, Pharmaceutical industry, Online shopping

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy Kidd, M.D., president & chief executive officer, will participate in a virtual fireside chat at the SVB Securities Global Biopharma Conference on Wednesday, February 15, 2023 at 10:00 a.m.
  • ET.
  • A live webcast of the fireside chat will be available to view on the “Events and Presentations” page in the “Investors & Media” section of Aptinyx’s website at https://ir.aptinyx.com and will be archived on Aptinyx’s website for 30 days following the event.

Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience

Retrieved on: 
Jeudi, novembre 10, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Private Securities Litigation Reform Act, NMDA, Government budget balance, RATS, U.S. Securities and Exchange Commission, Opioid use disorder, APTX, Fear, Connective tissue disease, Annual report, NASDAQ, Brain, CA, Inc., NMDAR, Security (finance), Post-traumatic stress disorder, Central nervous system, Society, Trial of the century, Pharmaceutical industry

The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic stress disorder and opioid use disorder.

Key Points: 
  • The presentations include preclinical data supporting the development of NYX-783, an NMDA receptor positive allosteric modulator in post-traumatic stress disorder and opioid use disorder.
  • Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
  • All forward-looking statements contained in this press release speak only as of the date on which they were made.
  • Aptinyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Mardi, novembre 8, 2022
Mental Health, Health, Neurology, General Health, Clinical Trials, Pharmaceutical, Biotechnology, PTSD, Investor, Fibromyalgia, Private Securities Litigation Reform Act, Initiative, National, NMDA, Government budget balance, HEAL, U.S. Securities and Exchange Commission, OUD, Research and development, Yale School of Medicine, Opioid use disorder, Webcast, Research, Annual report, NIH, Clinician, Oxycodone, R, Connective tissue disease, Chronic pain, Addiction, Brain, National Institute on Drug Abuse, Safety, ID, DSM-5, National Institute, Pharmacokinetics, Form 10-K, Patient, Security (finance), Administration, Post-traumatic stress disorder, Central nervous system, Yale University, NIDA, COVID-19, Trial of the century, Medical imaging, Pharmaceutical industry, Risk management

The study will be administered by the Yale Interdisciplinary Stress Center through a research collaboration with Aptinyx.

Key Points: 
  • The study will be administered by the Yale Interdisciplinary Stress Center through a research collaboration with Aptinyx.
  • In August 2022, Aptinyx announced that the primary endpoint was not achieved in its Phase 2b study of NYX-2925 in patients with fibromyalgia.
  • Net Loss: Net loss was $15.3 million for the third quarter of 2022, compared to a net loss of $21.2 million for the third quarter of 2021.
  • ET to review its financial results and highlights for the third quarter of 2022 and subsequent period.

Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant

Retrieved on: 
Jeudi, novembre 3, 2022
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, Blood pressure, Yale School of Medicine, Central nervous system, Annual report, Initiative, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NIDA, Private Securities Litigation Reform Act, Research, Foundation, Food, NMDA, Form 10-K, Yale University, Human, Inc., HEAL, Connective tissue disease, Safety, Respiratory rate, Brain, Heart rate, APTX, Addictive behavior, National, Trial of the century, Nasdaq, Opioid, Post-traumatic stress disorder, Methadone, National Institute, Opioid use disorder, Buprenorphine, U.S. Securities and Exchange Commission, Oxycodone, Fast Track, Government budget balance, National Institute on Drug Abuse, Addiction, Rainforest Foundation Fund, OUD, Psychiatry, NIH, Drug, PTSD, Fentanyl, Patient, Naltrexone, Pharmacokinetics, Program, Pharmaceutical industry

NYX-783 is an NMDA receptor positive allosteric modulator also in Phase 2b development by Aptinyx for the treatment of post-traumatic stress disorder (PTSD).

Key Points: 
  • NYX-783 is an NMDA receptor positive allosteric modulator also in Phase 2b development by Aptinyx for the treatment of post-traumatic stress disorder (PTSD).
  • Additional preclinical research has demonstrated NYX-783s potential as a treatment option for the millions of people struggling with opioid use disorder.
  • We are pleased to continue our collaboration with Aptinyx for the evaluation of NYX-783 for the treatment of OUD, said Dr. DiLeone.
  • The company has multiple product candidates in clinical development in central nervous system indications, including cognitive impairment, post-traumatic stress disorder, and opioid use disorder.

Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

Retrieved on: 
Mardi, octobre 18, 2022
Biotechnology, Pharmaceutical, Health, Neurology, Lists of diseases, Connective tissue disease, Brain, Government budget balance, Webcast, Investor, ID, Central nervous system, APTX, Nasdaq, NMDA, Inc., Pharmaceutical industry

ET to report third quarter 2022 financial results and discuss recent business highlights.

Key Points: 
  • ET to report third quarter 2022 financial results and discuss recent business highlights.
  • To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international) and refer to conference ID 141144.
  • A live audio webcast of the event will be available on the Investors & Media section of Aptinyxs website at https://ir.aptinyx.com .
  • The company has two product candidates in clinical development in central nervous system indications, including cognitive impairment and post-traumatic stress disorder.

Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

Retrieved on: 
Jeudi, août 25, 2022
Biotechnology, Other Health, Health, General Health, Pharmaceutical, Neurology, Mental Health, Other Science, Research, Science, Clinical Trials, Government budget balance, Security (finance), COVID-19, Human, Connective tissue disease, Safety, Post-traumatic stress disorder, Form 10-K, Central nervous system, Fibromyalgia, APTX, Brain, Disease, Primate, Lewy body, Memory, Even and odd functions, Lists of diseases, U.S. Securities and Exchange Commission, Inc., Patient, Cognitive deficit, Nasdaq, Attention, Twitter, Dementia, Annual report, Private Securities Litigation Reform Act, Neurodegeneration, CNS, Pharmaceutical industry, NMDA

The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study to evaluate the safety and potential cognitive benefits of NYX-458 in 99 patients with mild cognitive impairment or mild dementia associated with Parkinsons disease or dementia with Lewy bodies.

Key Points: 
  • The Phase 2 study is a randomized, double-blind, parallel-design, placebo-controlled study to evaluate the safety and potential cognitive benefits of NYX-458 in 99 patients with mild cognitive impairment or mild dementia associated with Parkinsons disease or dementia with Lewy bodies.
  • Cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies is characterized by a broad range of deficits related to attention, memory, and executive function.
  • Current treatment options for cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies are limited, with only one approved treatment for Parkinsons disease dementia and no treatments approved for dementia with Lewy bodies.
  • NYX-458 is a novel oral NMDA receptor positive allosteric modulator currently in clinical development for the treatment of cognitive impairment associated with Parkinsons disease and dementia with Lewy bodies.

Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

Retrieved on: 
Vendredi, août 12, 2022
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, FDA, U.S. Securities and Exchange Commission, Government budget balance, Chronic pain, Trial of the century, Private Securities Litigation Reform Act, NRS, Brain, Inc., Security (finance), Annual report, Pain, Patient, COVID-19, Central nervous system, Safety, Post-traumatic stress disorder, Connective tissue disease, Lists of diseases, Fibromyalgia, Nasdaq, APTX, PTSD, NMDA, Medical imaging, Pharmaceutical industry

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced results from a Phase 2b clinical study evaluating the effects of NYX-2925 in patients with fibromyalgia.
  • We are very disappointed that, despite the evidence of activity observed in a prior biomarker study in fibromyalgia patients, in this follow-up Phase 2b study NYX-2925 did not achieve statistical separation from placebo, said Andy Kidd, M.D., president and chief executive officer of Aptinyx.
  • The results of this study highlight the challenges of developing novel therapies for pain.
  • The Phase 2b fibromyalgia study was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of NYX-2925 in approximately 300 patients with fibromyalgia.

Aptinyx Reports Second Quarter 2022 Financial Results and Recent Highlights

Retrieved on: 
Jeudi, août 4, 2022
Biotechnology, Pharmaceutical, Health, Neurology

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the companys clinical-stage pipeline of novel NMDA receptor modulators.

Key Points: 
  • Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today reported financial results for the second quarter of 2022 and provided key business updates across the companys clinical-stage pipeline of novel NMDA receptor modulators.
  • We are on track to complete enrollment in the coming weeks and expect to report data in the first quarter of 2023.
  • Net Loss: Net loss was $17.7 million for the second quarter of 2022, compared to a net loss of $19.8 million for the second quarter of 2021.
  • ET to review its financial results and highlights for the second quarter of 2022 and subsequent period.